Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

نویسندگان

  • Christina Ruhlmann
  • Jørn Herrstedt
چکیده

Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with cancer. The knowledge of the pathogenesis and neuropharmacology of CINV has expanded enormously over the last decades, the most significant discoveries being the role of 5-hydroxytryptamine (5-HT)(3)- and neurokinin (NK)(1) receptors in the emetic reflex arch. This has led to the development of two new classes of antiemetics acting as highly selective antagonists at one of these receptors. These drugs have had a huge impact in the protection from chemotherapy-induced vomiting, whereas the effect on nausea seems to be limited. The first NK(1) receptor antagonist, aprepitant, became clinically available in 2003, and casopitant, the second in this class of antiemetics, has now completed phase III trials. This review delineates the properties and clinical use of casopitant in the prevention of CINV.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

TCRM-4026-Casopitant: a novel NK1-receptor antagonist in

Correspondence: Christina Ruhlmann Odense University Hospital, Department of Oncology, Sdr. Boulevard 29, DK-5000 Odense C, Denmark Tel +45 6541 3834 email christina.ruhlmann@ouh. regionsyddanmark.dk Abstract: Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with cancer. The knowledge of the pathogenesis and neuropharmaco...

متن کامل

New options and controversies in the management of chemotherapy-induced nausea and vomiting.

PURPOSE An expanding array of options for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), including regimens containing olanzapine or recently approved neurokinin 1 (NK1) receptor antagonists, are reviewed. SUMMARY Up to 80% of patients receiving chemotherapy have CINV. Current practice guidelines recommend that patients treated with highly emetogenic chemotherapy...

متن کامل

New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most challenging adverse events of chemotherapy, and one that has substantial negative effects on patients, clinicians, and the wider health care system. Use of CINV prophylaxis consistent with clinical practice guidelines is essential for attaining optimal CINV control. In recent years, there has been a dramatic improvement in ...

متن کامل

Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting.

Despite major advances, emesis remains a major problem in the context of cancer chemotherapy and in the postoperative period. A better understanding of the relevant neurocircuitry, especially the central pattern generator responsible for emesis and the central role of substance P, led to the development of a new class of antiemetics: the neurokinin-1 (NK1) receptor antagonists. Aprepitant is th...

متن کامل

The difficult trials.

addition of the NK1-receptor antagonist, casopitant (day 1–3), to a combination of ondansetron (day 1–3) plus dexamethasone (day 1) was investigated in patients receiving moderately emetogenic chemotherapy [4]. In a subpopulation (n = 123) treated with oxaliplatin-based chemotherapy, the 0–120-h complete response rate (no emesis and no need for rescue antiemetics) was improved from approximatel...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Therapeutics and Clinical Risk Management

دوره 5  شماره 

صفحات  -

تاریخ انتشار 2009